AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01308229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nile PAX® paclitaxel-eluting coronary stent
Description: Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions
Study NCT00785343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reo Go robotic arm trainer
Description: Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
Study NCT00785343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Occupational therapy that is the current standard of care
Study NCT03013049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non cultured epidermal cell suspension
Description: Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
Study NCT03013049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non cultured epidermal cell suspension
Description: Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
Study NCT03013049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non cultured dermal cell suspension
Description: Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
Study NCT04673916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Healing evaluation
Description: Treatments were topically applied for 5 days
Study NCT01522261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Bowel Prep
Description: Patients randomized to MBP will complete procedure per standard instructions.
Study NCT01522261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Mechanical Bowel Prep
Description: Patient randomized to fleets enemas only prior to surgery
Study NCT00007020 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cholic Acids
Description: 10-15 mg/kg body weight/day taken orally.
Study NCT00999960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Radical Prostatectomy (without a simulator)
Description: without simulator
Study NCT00999960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Radical Prostatectomy (with a simulator)
Description: Learning with a simulator
Study NCT04058548 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sit to stand test
Description: Participants will complete a sit to stand test in addition to a 6 minute walk test
Study NCT01073917 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spontaneous Breathing
Study NCT01073917 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pressure Controlled Ventilation
Study NCT01073917 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pressure Support Ventilation
Study NCT00167388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: feed during blood transfusion
Description: babies receiving the intervention are fed during the PRBC transfusion
Study NCT00167388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feed during blood transfusion
Description: babies receiving the intervention are fed during the PRBC transfusion
Study NCT01113346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filtrum-STI (lignin hydrolytic)
Description: For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.~For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days.
Study NCT01113346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days.
Study NCT02881619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac
Description: The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
Study NCT02881619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will receive a single-dose of placebo one hour before the bleaching procedure.
Study NCT04214639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-126 Gel
Description: IDP-126 Gel applied topically to the face once daily for 12 weeks.
Study NCT04214639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-126 Vehicle Gel
Description: IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
Study NCT00185601 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet Diabetes Self-Management Program
Study NCT00185601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Diabetes Self-Management Program
Study NCT01756118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: A minimum of 3 dose levels
Study NCT00687102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: oral tamoxifen plus placebo daily for 5 years
Study NCT00687102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene
Description: oral raloxifene plus placebo daily for 5 years
Study NCT00734071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate-release tablets
Study NCT00734071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules
Study NCT00843154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan and standard chronic heart disease therapy
Description: Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
Study NCT00843154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chronic heart disease therapy
Description: Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
Study NCT01088854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: unique session of 30-minute of continuous airway positive pressure
Study NCT02886871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step Goal Delivery by Smartphone
Study NCT02886871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Goal Delivery by Smartphone
Study NCT01989611 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: emtricitabine / tenofovir 200/300 mg
Description: Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
Study NCT01934309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TB reminders
Description: The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
Study NCT03864913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone injection
Description: SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
Study NCT03495999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hyperuricemia
Description: serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women
Study NCT03864913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PedsQL questionnarie
Description: Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.
Study NCT00625859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
Study NCT03864913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masculinizing effects questionnaire
Description: Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
Study NCT03864913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication experience questionnaire
Description: Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
Study NCT04387266 — intervention group
Intervention type: RADIATION
Intervention: modified reduce-volume target IMRT
Description: The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
Study NCT00963924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
Study NCT00963924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: 40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
Study NCT03247725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain app
Description: Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
Study NCT03247725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (medical)
Description: Patients will be offered the usual treatment for their pain, which is not changed by study participation
Study NCT03247725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (medical)
Description: Patients will be offered the usual treatment for their pain, which is not changed by study participation
Study NCT02593656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein
Description: Protein-pacing throughout the day and exercise training for 12 weeks
Study NCT02593656 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Protein
Description: Normal protein intake throughout the day and exercise training for 12 weeks
Study NCT05373693 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single vision lens
Description: Wear single vision lens
Study NCT05373693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: +2D PDL
Description: Wear Peripheral defocus lense with +2D
Study NCT05373693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: +3D PDL
Description: Wear Peripheral defocus lense with +3D
Study NCT05373693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: +4D PDL
Description: Wear Peripheral defocus lense with +4D
Study NCT01292083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given IV
Study NCT01292083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00963924 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Remediation
Description: 40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
Study NCT00446095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: 200 mg PO BID
Study NCT02262988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee replacement
Description: Total knee replacement (TKA)
Study NCT00625859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be given to subjects.
Study NCT04389788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carboxy therapy
Description: 6 sessions of carboxy therapy every 2 weeks
Study NCT04389788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermapen with topical glutathione
Description: 6 sessions of Dermapen microneedling with topical glutathione every 2 weeks
Study NCT01292083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01292083 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT01292083 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies
Study NCT01292083 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies
Study NCT01292083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo definitive breast surgery
Study NCT03885544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Lacto-ovo vegetarian diet
Description: Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian (LOV) diet for 3 weeks. All foods will be provided to subjects during the intervention. Each subject's energy requirement will be estimated using sex-specific equations published by the Institute of Medicine for weight maintenance during the intervention.
Study NCT03885544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled Unprocessed red meat diet
Description: The unprocessed red meat diet will be the same as the LOV diet except that one 3-ounce portion of unprocessed red meat per day, 7 days per week (21 oz/wk) will be included. The unprocessed red meat will include beef tenderloin and pork loin. All foods will be provided to subjects during the intervention.
Study NCT04184531 — intervention group
Intervention type: OTHER
Intervention: Medical Data Collect
Description: It is a retrospective clinical study and we will collect only the medical data registered in our hospital software
Study NCT03605797 — intervention group
Intervention type: OTHER
Intervention: follow up of cases fixed by posterior tension band plate
Description: Follow up of the reduction and functional outcome evaluation using the Majeed functional outcome score
Study NCT01813669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Coping Group
Description: The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions
Study NCT04199299 — intervention group
Intervention type: DEVICE
Intervention: Heart rate and respiration rate sensors
Description: The use of sensors to monitor physiological variables (e.g. heart rate, sleep). The design is a before-and-after comparison with respect to whether the use of sensors has changed the caregivers' practice and their (perceived) understanding of the participant. The frequency of participants' self harm or aggressive behavior after as compared to before the introduction of pulse- and respiration monitors will also be charted.
Study NCT03822676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic pancreatic stent
Description: Prophylactic pancreatic stent before segmental pancreatic surgery
Study NCT00837655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer
Description: sevelamer tablets, 800 mg (Renagel(r), Genzyme Inc). The initial daily dose of sevelamer will be 2400 mg (800 mg x 3). After the first week of treatment the dose will be increased to 4800 mg. If treatment with sevelamer is well tolerated and if a phosphate concentration of \<1.8 mmol/l is not obtained, the dose may be increased further. The maximum daily dose of sevelamer will be 9600 mg. If a patient experiences side effects, the dose of sevelamer will be reduced to the highest acceptable dose, and, if a phosphate concentration of \<1.8 mmol/l is not obtained, the treatment will be supplemented with calcium carbonate in a dose tolerated by the patient.
Study NCT00837655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration \<1.8 mmol/l.
Study NCT01888796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Study NCT01888796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01908361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unilateral Hybrid (InMotion3 plus CIT) Intervention
Description: During the 3-week InMotion3 period, participants will receive 5 minutes of muscle tone normalization preparation and passive range of motion, then 85 minutes of training using the InMotion3 robot. The participants will practice about 5 to 8 minutes of passive, 30 to 35 minutes of assisted-active, and 5 to 8 minutes of active motions in wrist and forearm, respectively.~During the 3-week CIT period, participants will receive intensive training of the affected UL in functional tasks with behavioral shaping for 1.5 hours/weekday and will be asked to wear a mitt to restrict the unaffected UL for 6 hours daily. The shaping techniques will involve individualized task selection, graded task difficulty, verbal feedback, prompting, physical assistance with movements, and modeling. Caregivers will use daily logs to document hours of mitt wearing outside the one-on-one intervention sessions.
Study NCT01908361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bilateral Hybrid (BMT plus BAT) Intervention
Description: During the 3-week BMT period, patients will play a simple computer game (e.g., picking up apples) that tracks patient movements to provide instant visual feedback. The therapist will also provide verbal feedback. In each training session, the patient will practice 600 to 800 repetitions of passive-passive mode for 15 minutes, 600 to 800 repetitions of active-passive mode for 15 to 20 minutes, and 150 to 200 repetitions of active-active mode for 5 minutes, respectively, for the forearm pronation-supination and the wrist flexion-extension.~During the 3-week BAT period, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs, such as lifting two cups, picking up two pegs, grasping and releasing two towels, and wiping the table with both hands.
Study NCT01908361 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Participants in CR group will receive therapist-mediated functional tasks training based on neurodevelopmental techniques with emphasis on functional tasks and muscle strengthening that will involve (1) active/passive range of motions, abnormal muscle tone/reflex inhibition techniques (such as stretching and/or weight bearing), and strengthening of affected arm for 15 to 20 minutes, (2) functional tasks for training fine motor or manual dexterity for 20 minutes, and (3) activities of daily living or functional tasks involving gross motor activities, coordination tasks, transition, mobility, and posture/balance for 15 to 20 minutes. The activities will be individualized according to the level of impairment and the needs of the patients.